Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym

February 21, 2012 12:14 PM EST Send to a Friend
Get Alerts CORT Hot Sheet
Price: $3.16 -1.25%

Rating Summary:
    5 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade CORT Now!
Join SI Premium – FREE
Several analyst firms have revised price targets and estimates on shares of Corcept Therapeutics (Nasdaq: CORT) following news of FDA approval for its Korlym. Corcept shares last traded at $4.42, up more than 46 percent from Friday's closing price.
  • JMP Securities - from $9 to $11, Market Outperform maintained
  • Stifel Nicolaus - from $7 to $9, Buy maintained
  • Ladenburg Thalmann - from $6 to $7, Buy maintained
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Corcept.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel Nicolaus, JMP Securities, Ladenburg Thalmann Financial Services

Add Your Comment